Wealthfront Advisers LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 1763921
Palo Alto, CA
Position in SLS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$587,772
+$539,398 QoQ
Shares Held
39,822
+248.2% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#82
of 189 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Wealthfront Advisers LLC holds $35,327,037 across 19 Biotechnology names. SLS ranks #7 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
41,608 | $20,667,941 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,006 | $4,368,521 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
9,554 | $2,876,040 | |
| 4 | INSM |
INSMED Inc
|
17,511 | $1,867,022 | |
| 5 | INCY |
Incyte Corp
|
9,753 | $1,105,600 | |
| 6 | MRNA |
Moderna, Inc.
|
15,621 | $1,093,938 | |
| 7 | SLS |
SELLAS Life Sciences Group, Inc.
This page
|
39,822 | $587,772 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
8,602 | $469,153 |
All Filings in SLS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $587,772 | 39,822 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $48,374 | 11,436 | Shares | Sole | 2026-05-05 | |
| No filing history on record for this holder in this stock. | ||||||